JUBLPHARMA - Swing Trade Analysis with AI Signals

Last Updated Time : 05 Nov 25, 7:43 am

Swing Trade Rating: 3.2

📉 Jubilant Pharmova shows bullish technicals and low debt, but weak fundamentals and recent losses make it a cautious swing trade.

🎯 Optimal Entry Price: ₹1,150–₹1,160

🚪 Exit Target (if already holding): ₹1,200–₹1,220

🔍 Positive

• 📈 MACD at 14.9 indicates strong bullish momentum.
• 📊 RSI at 64.4 suggests strength, though nearing overbought territory.
• 📈 Price above 50 DMA and 200 DMA (₹1,109 and ₹1,059), confirming short-term uptrend.
• 📈 DII holding increased by 1.01%, showing domestic institutional confidence.
• 📉 Debt-to-equity ratio of 0.02 reflects strong financial discipline.

⚠️ Limitation

• 📉 ROCE of 2.91% and ROE of 1.04% indicate poor capital efficiency.
• 📉 Quarterly PAT dropped from ₹4.10 Cr to -₹48.0 Cr, showing severe earnings pressure.
• 📉 Volume below weekly average (2.67L vs 4.01L), suggesting weak momentum.
• 📉 EPS of ₹1.15 is low relative to price, making valuation unattractive.
• 📉 FII holding declined by 0.84%, reflecting cautious foreign sentiment.

📉 Company Negative News

• 📉 Q2FY26 results showed a net loss of ₹48 Cr due to margin compression and operational inefficiencies

  Trendlyne

  .

• 📉 FII outflows suggest lack of confidence in near-term recovery

  Trendlyne

  .

📈 Company Positive News

• 📈 DII inflows indicate long-term optimism despite short-term challenges

  Trendlyne

  .

• 📈 Technical breakout above key moving averages may attract swing traders

  Trendlyne

  .

• 📈 Analysts forecast gradual recovery in earnings over the next few quarters

  Simply Wall St

  .

💊 Industry

• 💊 Pharma sector benefits from long-term demand and innovation in generics and specialty drugs.
• 📉 Regulatory hurdles and pricing pressures remain key risks.

✅ Conclusion

• 📉 Jubilant Pharmova is a cautious swing trade candidate with bullish technicals but weak fundamentals.
• 🎯 Entry near ₹1,150–₹1,160 with exit around ₹1,200–₹1,220 is recommended for short-term traders.
• 📊 Long-term investors should wait for earnings recovery and margin improvement before increasing exposure.

Sources

Simply Wall St

+2

I can also compare Jubilant Pharmova with peers like Aurobindo Pharma or Lupin to identify stronger swing setups in the pharma space.